Edition:
United States

Nivalis Therapeutics Inc (NVLS.OQ)

NVLS.OQ on NASDAQ Stock Exchange Global Market

2.79USD
10:42am EDT
Change (% chg)

$0.05 (+1.82%)
Prev Close
$2.74
Open
$2.76
Day's High
$2.81
Day's Low
$2.75
Volume
2,800
Avg. Vol
84,018
52-wk High
$9.35
52-wk Low
$2.01

NVLS.OQ

Chart for NVLS.OQ

About

Nivalis Therapeutics, Inc. is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration. The Company's S-nitrosogl... (more)

Overall

Beta: --
Market Cap(Mil.): $42.90
Shares Outstanding(Mil.): 15.66
Dividend: --
Yield (%): --

Financials

  NVLS.OQ Industry Sector
P/E (TTM): -- 47.82 29.72
EPS (TTM): -2.03 -- --
ROI: -45.29 -2.46 13.00
ROE: -45.29 5.18 14.15

BRIEF-Nivalis Therapeutics announces results from phase 2 clinical trial of Cavosonstat

* Nivalis Therapeutics announces results from phase 2 clinical trial of Cavosonstat added to Ivacaftor for treatment of cystic fibrosis Source text for Eikon: Further company coverage:

Feb 23 2017

BRIEF-Nivalis Therapeutics reports Q4 loss per share of $0.50

* Nivalis Therapeutics reports fourth quarter and full-year 2016 financial results

Feb 13 2017

BRIEF-Nivalis therapeutics announces corporate restructuring

* Nivalis Therapeutics Inc says intends to complete a reduction in force affecting 25 employees

Jan 12 2017

BRIEF-Nivalis Therapeutics announces results from Phase 2 clinical trial of Cavosonstat

* Nivalis therapeutics announces results from Phase 2 clinical trial of Cavosonstat for treatment of cystic fibrosis

Nov 28 2016

BRIEF-Nivalis Therapeutics announces completion of enrollment in second phase 2 study of cavosonstat for treatment of cystic fibrosis

* Nivalis therapeutics announces completion of enrollment in second phase 2 study of cavosonstat for treatment of cystic fibrosis

Nov 14 2016

BRIEF-Nivalis Therapeutics reports Q3 loss per share $0.48

* Nivalis Therapeutics reports third quarter 2016 financial results

Nov 07 2016

BRIEF-Nivalis Therapeutics says, on Nov.1, board approved increase in size of board to seven directors - SEC filing

* On November 1, board approved an increase in size of board of directors to seven - SEC filing Source text : http://bit.ly/2fmrax9 Further company coverage:

Nov 03 2016

More From Around the Web

Earnings vs. Estimates